(NASDAQ: ARWR) Arrowhead Pharmaceuticals's forecast annual revenue growth rate of -24.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Arrowhead Pharmaceuticals's revenue in 2025 is $545,209,000.On average, 8 Wall Street analysts forecast ARWR's revenue for 2025 to be $97,848,301,211, with the lowest ARWR revenue forecast at $75,292,357,162, and the highest ARWR revenue forecast at $126,292,847,808. On average, 8 Wall Street analysts forecast ARWR's revenue for 2026 to be $41,570,164,341, with the lowest ARWR revenue forecast at $14,044,814,240, and the highest ARWR revenue forecast at $64,313,372,580.
In 2027, ARWR is forecast to generate $47,886,602,037 in revenue, with the lowest revenue forecast at $19,154,530,335 and the highest revenue forecast at $74,173,743,639.